Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML | Leukemia
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (AL Stock Vector Image & Art - Alamy
Genetic factors influencing cytarabine therapy | Pharmacogenomics
Pan‑RAF inhibitor LY3009120 is highly synergistic with low‑dose cytarabine, but not azacitidine, in acute myeloid leukemia with <em>RAS</em> mutations
Ara-C metabolism. Ara-C: Cytarabine; Ara-CDP: Ara-C diphosphate;... | Download Scientific Diagram
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial - Jädersten - 2022 - Journal of Internal Medicine - Wiley Online Library
Molecules | Free Full-Text | Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells
Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations - Experimental Hematology
Cytarabine-resistant (320nM) acute myeloid leukemia (AML) MOLM-13 cell line
SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival | Leukemia
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia | Haematologica
Primary AML cells and cell lines resistant to cytarabine, daunorubicin... | Download Scientific Diagram
Anti-leukemia effects of Ara-C@HFn and free Ara-C in AML mouse models.... | Download Scientific Diagram
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia | Nature Communications
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells - ScienceDirect
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota | Cancer Chemotherapy and Pharmacology
The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells - ScienceDirect
A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model - ScienceDirect
IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review
Smart and Generalizable Cytarabine Derivative-Triggered Nanoparticles for Synergistic Therapy of Relapsed/Refractory Acute Myeloid Leukemia | ACS Applied Materials & Interfaces
IJMS | Free Full-Text | Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia | Pharmacogenomics
